CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

RealTime Software Solutions Acquires Complion

RealTime Software Solutions Acquires...

What role does artificial intelligence play in the employment process?

What role does artificial...

Why AI is Used for Quality Management in Life Science

Why AI is Used for Quality Management...

Application of AI in Genetics

Application of AI in Genetics

How Artificial Intelligence Impacts Biotechnology

How Artificial Intelligence Impacts...

Akanta's Contextual Intelligence 360 to Enhance Customer Experience

Akanta's Contextual Intelligence 360...

MMIT/Evaluate to Boost Pharma Analytics After Acquisition of Panalgo

MMIT/Evaluate to Boost Pharma...

Syneos Health's Acquisition of RxDataScience to Help Boost Product Development

Syneos Health's Acquisition of...

RealTime Software Solutions Acquires Complion

RealTime Software Solutions Acquires...

What role does artificial intelligence play in the employment process?

What role does artificial...

Why AI is Used for Quality Management in Life Science

Why AI is Used for Quality Management...

Application of AI in Genetics

Application of AI in Genetics

How Artificial Intelligence Impacts Biotechnology

How Artificial Intelligence Impacts...

Akanta's Contextual Intelligence 360 to Enhance Customer Experience

Akanta's Contextual Intelligence 360...

MMIT/Evaluate to Boost Pharma Analytics After Acquisition of Panalgo

MMIT/Evaluate to Boost Pharma...

Syneos Health's Acquisition of RxDataScience to Help Boost Product Development

Syneos Health's Acquisition of...

Role of AI in the Life Sciences Sector

Life Sciences Review | Friday, July 30, 2021
Tweet

Life science firms that use artificial intelligence can avoid IP ownership difficulties by clarifying who owns AI-related intellectual property rights in employment, licensing, or purchase agreements.


FREMONT, CA : Artificial intelligence (AI) is a fast-growing sector of the life sciences industry, with applications in drug development, biotechnology, medical diagnosis, clinical trials, precision and customized medicine, and patient monitoring. The increased availability of ‘big data’ is likely to blame for the current increase in AI use in this area. Machine learning, deep learning, and natural language processing are examples of AI technologies that can be used to process large data sets to find novel medication candidates, optimize drug dosing, match patients to drug trials, and diagnose diseases.


Recognizing this potential, worldwide biopharma businesses have made significant investments in AI technology, with the AI in the life sciences market valued at USD 1092.44 million in 2019 and predicted to reach USD 3445.60 million by 2025.


Unsurprisingly, investors in this industry are eager to safeguard their AI-related breakthroughs with intellectual property. However, unlike traditional life sciences ideas, IP protection for AI-related innovations presents basic concerns of inventorship, patent eligibility, and public disclosure that the current US patent system does not simply address.


 


For example, the United States Patent and Trademark Office (USPTO) rejected the notion that an AI ‘machine’ can be an inventor last year. Consider the following two scenarios in the pharmaceutical industry:



  • Scientists at a pharmaceutical company use AI to help screen and identify new drugs by instructing AI to perform specific tasks; and

  • A pharmaceutical company purchases an AI system from a third party (for example, IBM), trains the system with a proprietary dataset, and uses the system to design a new drug with little or no human interaction.


AI-Related Intellectual Property (IP) Rights Should Be Defined Contractually


First, life science firms that use AI can avoid IP ownership difficulties by clarifying who owns AI-related IP rights in employment, licensing, or purchase agreements. Such agreements should also state who will control the data, information, or outcomes generated by AI, who will be able to use it, and how they will be utilized. For example, in the second case, IBM may explicitly maintain all IP rights in the AI system while licensing specific IP rights in the AI system's output, such as new medication compounds, to a pharmaceutical business. Furthermore, such agreements should specify who is responsible for the actions conducted and outcomes obtained by AI systems now and in the future.


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/role-of-ai-in-the-life-sciences-sector--nwid-481.html